Human papillomavirus infection in women in four regions of Senegal

Journal of Medical Virology

Volumn 86, Issue 2, 2014, Pages 248-256

  Mbaye, El Hadji Seydou ^a,b   Gheit, Tarik ^a   Dem, Ahmadou ^b   Mckay Chopin, Sandrine ^a   Toure Kane, Ndeye Coumba ^b   Mboup, Souleymane ^b   Tommasino, Massimo ^a   Sylla, Bakary S ^a   Boye, Cheikh Saad Bouh ^b  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b Centre Hospitalier Universitaire Aristide Le Dantec de Dakar   (Senegal)

Author keywords

Cervical cancer; Papillomavirus; Senegal

Indexed keywords

DNA;

ADULT; AGED; ARTICLE; FEMALE; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 53; MAJOR CLINICAL STUDY; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; PAPILLOMAVIRUS INFECTION; PREVALENCE; SENEGAL; UTERINE CERVIX CANCER; VIRUS DETECTION; WOMEN'S HEALTH;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPES; PAPILLOMAVIRIDAE;

CERVICAL CANCER; PAPILLOMAVIRUS; SENEGAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENOTYPE; GENOTYPING TECHNIQUES; HUMANS; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; SENEGAL; YOUNG ADULT;

EID: 84890141885     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23719     Document Type: Article

References (41)

1. Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, Ferlay J. 2011. Worldwide burden of cervical cancer in 2008. Ann Oncol 22:2675-2686.
2. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, Koliopoulos G, Naucler P, Sankaranarayanan R, Peto J. 2012. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 30:F88-F99.
3. Bayo S, Bosch FX, de Sanjosé S, Muñoz N, Combita AL, Coursaget P, Diaz M, Dolo A, van den Brule AJ, Meijer CJM. 2002. Risk factors of invasive cervical cancer in Mali. Int J Epidemiol 31:202-209.
4. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V. 2009. WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens-Part B: Biological agents. Lancet Oncol 10:321-322.
5. Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. 2010. Cervical human papillomavirus prevalence in 5 continents: Meta-analysis of 1 million women with normal cytological findings. J Infect Dis 202:1789-1799.
6. Castellsagué X, de Sanjosé S, Aguado T, Louie KS, Bruni L, Muñoz J, Diaz M, Irwin K, Gacic M, Beauvais O, Albero G, Ferrer E, Byrne S, Bosch FX. 2007. HPV and cervical cancer in the world, 2007 Report. Vaccine 25S:C1-C26.
7. Chan PK, Chang AR, Cheung JL, Chan DP, Xu LY, Tang NL, Cheng AF. 2002. Determinants of cervical human papillomavirus infection: Differences between high- and low-oncogenic risk types. J Infect Dis 185:28-35.
8. Clifford G, Franceschi S. 2005. HPV in sub-Saharan Africa [editorial]. Papillomavirus Rep 16:322-326.
9. Comar M, Iannacone MR, Casalicchio G, McKay-Chopin S, Tommasino M, Gheit T. 2012. Comparison of hybrid capture II, linear array, and a bead-based multiplex genotyping assay for detection of human papillomavirus in women with negative Pap test results and atypical squamous cells of undetermined significance. J Clin Microbiol 50:4041-4046.
10. Cuzick J, Beverley E, Ho L, Terry G, Sapper H, Mielzynska I, Lorincz A, Chan WK, Krausz T, Soutter P. 1999. HPV testing in primary screening of older women. Br J Cancer 81:554-558.
11. de Sanjosé S, Quint WGV, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, Lombardi LE, Banjo A, Menéndez C, Domingo EJ, Velasco J, Nessa A, Chichareon SC, Qiao YL, Lerma E, Garland SM, Sasagawa T, Ferrera A, Hammouda D, Mariani L, Pelayo A, Steiner I, Oliva E, Meijer CJ, Al-Jassar WF, Cruz E, Wright TC, Puras A, Llave CL, Tzardi M, Agorastos T, Garcia-Barriola V, Clavel C, Ordi J, Andújar M, Castellsagué X, Sánchez GI, Nowakowski AM, Bornstein J, Muñoz N, Bosch FX, Retrospective International Survey and HPV Time Trends Study Group. 2010. Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study. Lancet Oncol 11:1048-1056.
12. Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, Dubin G, HPV-010 Study Group. 2009. Comparison of the immunogenicity and safety of cervarix and gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 5:705-719.
13. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917.
14. Gheit T, Landi S, Gemignani F, Snijders PJ, Vaccarella S, Franceschi S, Canzian F, Tommasino M. 2006. Development of a sensitive and specific assay combining multiplex PCR and DNA microarray primer extension to detect high-risk mucosal human papillomavirus types. J Clin Microbiol 44:2025-2031.
15. Giuliano AR, Tortolero-Luna G, Ferrer E, Burchell AN, de Sanjosé S, Kjaer SK, Muñoz N, Schiffman M, Bosch FX. 2008. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine 26S:K17-K28.
16. Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, Balmaceda I, Greenberg MD, Alfaro M, Burk RD, Wacholder S, Plummer M, Schiffman M. 2000. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 92:464-474.
17. IARC (International Agency Research for on Cancer). 2007. Human papillomaviruses. IARC monographs on the evaluation of carcinogenic risks to humans. Vol. 90:
18. IARC (International Agency for Research on Cancer). 2011. Human papillomaviruses. IARC monographs on the evaluation of carcinogenic risks to humans. Vol. 100B.
19. Jacobs MV, Walboomers JM, Snijders PJ, Voorhorst FJ, Verheijen RH, Fransen-Daalmeijer N, Meijer CJ. 2000. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: The age-related patterns for high-risk and low-risk types. Int J Cancer 87:221-227.
20. Keita N, Clifford GM, Koulibaly M, Douno K, Kabba I, Haba M, Sylla BS, van Kemenade FJ, Snijders PJF, Meijer CJLM, Franceschi S. 2009. HPV infection in women with and without cervical cancer in Conakry, Guinea. Br J Cancer 101:202-208.
21. Lazcano-Ponce E, Herrero R, Muñoz N, Cruz A, Shah KV, Alonso P, Hernandez P, Salmeron J, Hernandez M. 2001. Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int J Cancer 91:412-420.
22. Lu B, Kumar A, Castellsagué X, Giuliano AR. 2011. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: A systematic review & meta-analysis. BMC Infect Dis 11:13.
23. Moscicki AB, Hills N, Shiboski S, Powell K, Jay N, Hanson E, Miller S, Clayton L, Farhat S, Broering J, Darragh T, Palefsky J. 2001. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 285:2995-3002.
24. National Agency of Statistics and Demography. 2012. Population of Senegal. http://au-senegal.com/Population.html
25. Ndiaye C, Alemany L, Ndiaye N, Kamaté B, Diop Y, Odida M, Banjo K, Tous S, Klaustermeier JE, Clavero O, Castellsagué X, Xavier Bosch F, Trottier H, de Sanjosé S. 2012. Human papillomavirus distribution in invasive cervical carcinoma in sub-Saharan Africa: Could HIV explain the differences? Trop Med Int Health 17:1432-1440.
26. Peyton CL, Gravitt PE, Hunt WC, Hundley RS, Zhao M, Apple RJ, Wheeler CM. 2001. Determinants of genital human papillomavirus detection in a US population. J Infect Dis 183:1554-1564.
27. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, Kane S, Desai S, Keskar VR, Rajeshwarkar R, Panse N, Dinshaw KA. 2009. HPV screening for cervical cancer in rural India. N Engl J Med 360:1385-1394.
28. Sasagawa T, Basha W, Yamazaki H, Inoue M. 2001. High-risk and multiple human papillomavirus infections associated with cervical abnormalities in Japanese women. Cancer Epidemiol Biomarkers Prev 10:45-52.
29. Schiller JT, Castellsague X, Garland SM. 2012. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 30(Suppl 5):F123-F138.
30. Schmitt M, Dondog B, Waterboer T, Pawlita M, Tommasino M, Gheit T. 2010. Abundance of multiple high-risk human papillomavirus (HPV) infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping assay. J Clin Microbiol 48:143-149.
31. Tay SK. 2012. Cervical cancer in the human papillomavirus vaccination era. Curr Opin Obstet Gynecol 24:3-7.
32. Thomas JO, Herrero R, Omigbodun AA, Ojemakinde K, Ajayi IO, Fawole A, Oladepo O, Smith JS, Arslan A, Muñoz N, Snijders PJF, Meijer CJLM, Franceschi S. 2004. Prevalence of papillomavirus infection in women in Ibadan, Nigeria: A population-based study. Br J Cancer 90:638-645.
33. Wall SR, Scherf CF, Morison L, Hart KW, West B, Ekpo G, Fiander AN, Man S, Gelder CM, Walraven G, Borysiewicz LK. 2005. Cervical human papillomavirus infection and squamous intraepithelial lesions in rural Gambia, West Africa: Viral sequence analysis and epidemiology. Br J Cancer 93:1068-1076.
34. WHO (World Health Organization). 2008. Human papillomavirus (HPV) vaccine, background paper, September 2008. http://www.who.int/immunization/documents/HPVBGpaper05032009.pdf
35. WHO (World Health Organization). 2009. Human papillomavirus vaccines WHO position paper. Wkly Epidemiol Rec 84:118-131. http://www.who.int/wer/2009/wer8415/en/index.html
36. WHO/ICO, Information Centre on HPV and Cervical Cancer. 2010a. Human papillomavirus and related cancers. United States of America Summary Report update. September 15, 2010. http://apps.who.int/hpvcentre/statistics/dynamic/ico/country_pdf/USA.pdf?CFID4005139&CFTOKEN=50211239
37. WHO/ICO, Information Centre on HPV and Cervical Cancer. 2010b. Human papillomavirus and related cancers. Senegal Summary Report update. September 15, 2010. http://apps.who.int/hpvcentre/statistics/dynamic/ico/country_pdf/SEN.pdf?CFID=4005139&CFTOKEN=50211239
38. WHO/ICO, Information Centre on HPV and Cervical Cancer. 2010c. Human papillomavirus and related cancers. World Summary Report update. November 15, 2010. http://apps.who.int/hpvcentre/statistics/dynamic/ico/country_pdf/XWX.pdf
39. World Health Surveys. 2003. Household surveys with geographical information system (GIS) multistage cluster sampling. Screening coverage among women aged 18-69. Geneva: WHO.
40. Xi LF, Toure P, Critchlow CW, Hawes SE, Dembele B, Sow PS, Kiviat NB. 2003. Prevalence of specific types of human papillomavirus and cervical squamous intraepithelial lesions in consecutive, previously unscreened, West-African women over 35 years of age. Int J Cancer 103:803-809.
41. Zhao C, Elishaev E, Yuan KH, Yu J, Austin RM. 2007. Very low human papillomavirus DNA prevalence in mature women with negative computer-imaged liquid-based pap tests. Cancer 111:292-297.